
Neuland Laboratories Commissions First Peptide Manufacturing Module, Eyes 18,000L Capacity
Neuland Laboratories has commenced commercial operations at the first module of its new peptide manufacturing facility, adding 7,000 litres of total reactor capacity for peptide API development and commercial-scale manufacturing. The module splits that capacity between 750 litres for solid-phase peptide synthesis (SPPS) and 6,250 litres for liquid-phase peptide synthesis (LPPS), and has reportedly already secured firm customer commitments of approximately $30 million.
The Hyderabad-based CDMO (contract development and manufacturing organization) is planning further modules to meet growing customer demand for peptide APIs, a category that has seen surging global demand on the back of GLP-1 and other peptide-based therapeutics. Module two is projected to bring overall reactor capacity up to 18,000 litres, and Neuland says foundational infrastructure for that expansion is already in place, allowing it to potentially begin work ahead of schedule once customer requirements are finalized.
Separately, Neuland also entered a long-term partnership with Gland Pharma in August 2026 to add a dedicated sterile API manufacturing suite at Gland's facility in Visakhapatnam, expected to provide around 1,400 kilograms of annual capacity for microparticle depot products and other complex sterile APIs. Together, the moves reflect a broader trend among Indian API manufacturers of investing in higher-complexity, higher-margin manufacturing capabilities rather than competing purely on volume in commodity APIs.
Photo (representative): a peptide synthesizer. Michael Pereckas, CC BY-SA 2.0, via Wikimedia Commons.